News Idorsia Ltd

Equities

IDIA

CH0363463438

Real-time Estimate Cboe Europe Other stock markets 03:45:25 2024-04-26 am EDT			5-day change	1st Jan Change
1.813 ^CHF	+4.08%		-5.48%	-11.92%

07:57am	Idorsia Gets EU Medicines Regulator's Positive Opinion for Resistant Hypertension Treatment	MT
Apr. 11	Swiss Market Index Falls as ECB Signals June Rate Cut	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Idorsia Gets EU Medicines Regulator's Positive Opinion for Resistant Hypertension Treatment	01:57am	MT
JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension	01:01am	GL
Idorsia publishes an invitation to a bondholder meeting	Apr. 23	GL
Idorsia : On April 17, 2024, Idorsia published an Unaudited Financial Status as of March 31, 2024, in connection with an upcoming bondholder meeting. Unaudited Financial Status	Apr. 17	PU
Idorsia publishes a Financial Status required for an upcoming bondholder meeting	Apr. 17	GL
Swiss Market Index Falls as ECB Signals June Rate Cut	Apr. 11	MT
Idorsia to Revise July 2024 Convertible Bond Terms, Conditions	Apr. 11	MT
Idorsia takes steps to address short-term liquidity needs	Apr. 11	GL
Idorsia's Chief Medical Officer to Step Down at March-end; Successor Named	Mar. 22	MT
Idorsia thanks Guy Braunstein for his years of service as he retires	Mar. 22	GL
Transcript : Idorsia Ltd - Special Call	Mar. 20
US FDA OKs Idorsia's Hypertension Treatment in Combination with Other Antihypertensive Drugs	Mar. 20	MT
US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives	Mar. 20	GL
Pharmaceutical Groups Idorsia, Viatris Finalize Collaboration to Develop Selatogrel, Cenerimod	Mar. 18	MT
Idorsia and Viatris successfully close the transaction for the global research and development collaboration	Mar. 18	GL
Idorsia, Viatris Partner to Develop, Commercialize Selatogrel, Cenerimod	Feb. 28	MT
Idorsia and Viatris enter into a significant global research and development collaboration	Feb. 28	GL
Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration	Feb. 28	PR
Sosei Group Changes Names of Company, Subsidiaries	Feb. 16	MT
US Futures Slightly Down, European Stocks Edge Up	Jan. 30	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Idorsia Ltd

Equities

IDIA

CH0363463438

Summary

Filters